Sensitization of tumor cells to radiation therapy through administration of endothelin agonists
View Patent ↗Methods to sensitize tumor cells to radiation therapy through the administration of an endothelin agonist such as the ET B agonist IRL1620.
1. A radiation combination therapy contributing to the treatment of a lymphoma in a patient in need thereof, the therapy comprising
administering a first radiation sensitizing compound and a second radiation sensitizing compound to the patient, wherein administration of the first radiation sensitizing compound increases oxygenation of the lymphoma, thereby sensitizing the lymphoma to radiation-induced cellular damage, and wherein the first radiation sensitizing compound is an endothelin B (ET B ) receptor agonist; and
administering a radiation to the patient, wherein administration of the radiation induces cellular damage to the lymphoma, thereby treating the lymphoma in the patient;
wherein administration of the first and the second radiation sensitizing compounds occurs before administration of the radiation to the patient.
2. The radiation combination therapy according to claim 1 , wherein the ET B receptor agonist includes ET-1, ET-2, ET-3, BQ3020, IRL1620, sarafotoxin S6c, or [Ala 1,3,11,15 ]ET-1, or combinations thereof.
3. The radiation combination therapy according to claim 2 , wherein the ET B receptor agonist is an IRL1620.
4. The radiation combination therapy according to claim 1 , wherein the second radiation sensitizing compound includes metronidazole, misonidazole, desmethylmisonidazole, pimonidazole, etanidazole, nimorazole, mitomycin C, RSU 1069, SR 4233, EO9, RB 6145, nicotinamide, 5-bromodeoxyuridine, 5-iododeoxyuridine, bromodeoxycytidine, fluorodeoxyuridine, hydroxyurea, or cisplatin, or mixtures thereof.
5. The radiation combination therapy according to claim 1 , wherein administration of the first and the second radiation sensitizing compounds comprises systemic or local administration.
6. The radiation combination therapy according to claim 1 , wherein administration of the first and the second radiation sensitizing compounds occurs through a route selected from the group consisting of oral administration, intra-tumoral administration, intravenous administration, intravesical administration, intraarterial administration, intranasal administration, and a combination thereof.
7. A radiation combination therapy for sensitizing a lymphoma to a radiation therapy in a patient in need thereof, the therapy comprising
administering a first radiation sensitizing compound and a second radiation sensitizing compound to the patient, wherein administration of the first radiation sensitizing compound increases oxygenation of the lymphoma, thereby sensitizing the lymphoma to radiation-induced cellular damage, and wherein the first radiation sensitizing compound is an endothelin B (ET B ) receptor agonist; and
administering a radiation to the patient, wherein administration of the radiation induces cellular damage to the lymphoma, thereby treating the lymphoma in the patient;
wherein administration of the first and the second radiation sensitizing compounds occurs before administration of the radiation to the patient.
8. The radiation combination therapy according to claim 7 , wherein the ET B receptor agonist includes ET-1, ET-2, ET-3, BQ3020, IRL1620, sarafotoxin S6c, or [Ala 1,3,11,15 ]ET-1, or combinations thereof.
9. The radiation combination therapy according to claim 8 , wherein the ET B receptor agonist is an IRL1620.
10. The radiation combination therapy according to claim 7 , wherein the second radiation sensitizing compound includes metronidazole, misonidazole, desmethylmisonidazole, pimonidazole, etanidazole, nimorazole, mitomycin C, RSU 1069, SR 4233, EO9, RB 6145, nicotinamide, 5-bromodeoxyuridine, 5-iododeoxyuridine, bromodeoxycytidine, fluorodeoxyuridine, hydroxyurea, or cisplatin, or mixtures thereof.
11. The radiation combination therapy according to claim 7 , wherein administration of the first and the second radiation sensitizing compounds comprises systemic or local administration.
12. The radiation combination therapy according to claim 7 , wherein administration of the first and the second radiation sensitizing compounds occurs through a route selected from the group consisting of oral administration, intra-tumoral administration, intravenous administration, intravesical administration, intraarterial administration, intranasal administration, and a combination thereof.